| | 78967-07-4 Basic information More.. |
| Product Name: | Mofezolac | | Synonyms: | Mofezolac;3,4-Bis(4-methoxyphenyl)isoxazole-5-acetic acid;Disopain;N-22;α-[3,4-Bis(4-methoxyphenyl)-5-isoxazolyl]acetic acid;2-(3,4-bis(4-Methoxyphenyl)isoxazol-5-yl)acetic acid;3,4-Bis(4-methoxyphenyl)-5-isoxazoleacetic acid;5-Isoxazoleacetic acid, 3,4-bis(4-methoxyphenyl)- | | CAS: | 78967-07-4 | | MF: | C19H17NO5 | | MW: | 339.34 | | EINECS: | | | Mol File: | 78967-07-4.mol |  |
Use
Mofezolac is a new non-steroidal analgesic antiinflammatory agent introduced in
Japan for the treatment of post-operative and post-traumatic pain, acute upper
respiratory tract pain, osteoarthritis, and lumbago. In in vfim studies, mofezolac
inhibits prostaglandin biosynthesis and platelet aggregation, reportedly through the
inhibition of cyclooxygenase. In animal studies, mofezolac showed more potent
suppression in various writhing models than agents such as ibuprofen, mefenamic
acid and aspirin. Mofezolac also has a potent inhibitory activity on the algesic
responses induced by the mechanical stimulus of the inflamed tissue. The
ulcerogenic effect of mofezolac on the gastric mucosa is far weaker than that of
indomethacin and other agents.
|
|
78967-07-4
Recommend Suppliers |
|